[HTML][HTML] S3-Leitlinie „Magenkarzinom”–

…, RD Hofheinz, H Höfler, T Höhler… - Zeitschrift für …, 2011 - thieme-connect.com
Diese Leitlinie wird als Lang-und Kurzversion mit einem zusätzlichen Leitlinienreport,
Evidenzberichten und einer Patientenleitlinie publiziert werden über die Homepages des …

German S3-guideline" Diagnosis and treatment of esophagogastric cancer"

…, S Höcht, RD Hofheinz, H Höfler, T Höhler… - Zeitschrift fur …, 2011 - elibrary.ru
MOEHLER M.* 1, AL-BATRAN SE, ANDUS T., ANTHUBER M., ARENDS J., ARNOLD D.,
AUST D., BAIER P., BARETTON G., BERNHARDT J., BOEING H., BÖHLE E., BOKEMEYER C., …

Differential regulation of interleukin-10 production by genetic and environmental factors–a twin study

…, R Fimmers, A Kruger, C Becker, C Rittner, T Höhler - Genes & …, 2002 - nature.com
Interleukin-10 (IL-10) has a critical role in the regulation of immune responses. The relative
contribution of genetic and environmental factors to IL-10 production is under debate. We …

Increased p53 mutation load in nontumorous human liver of wilson disease and hemochromatosis: oxyradical overload diseases

…, TR Billiar, C Trautwein, T Höhler… - Proceedings of the …, 2000 - National Acad Sciences
… We found a significantly high frequency of G:C to T:A transversions at codon 249 and C:G
to A:T transversions and C:G to T:A transitions at codon 250 in nontumorous liver tissue from …

Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins

T Höhler, E Reuss, N Evers, E Dietrich, C Rittner… - The Lancet, 2002 - thelancet.com
T Höhler designed the study, coordinated patients' recruitment, and wrote the report. E …
T Höhler has received a travel grant from GlaxoSmithKline, and J Vollmar is an employee of …

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised …

…, T Uchida, K Ando, T Kinoshita, T Höhler… - The Lancet …, 2018 - thelancet.com
Background Initial results from the ongoing GALLIUM trial have shown that patients with
follicular lymphoma have a longer progression-free survival after first-line immunochemotherapy …

Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a …

…, S Hegewisch-Becker, O Rubanov, G Baake, T Höhler… - Gut, 2013 - gut.bmj.com
Objective AIO-PK0104 investigated two treatment strategies in advanced pancreatic cancer (PC):
a reference sequence of gemcitabine/erlotinib followed by 2nd-line capecitabine was …

[HTML][HTML] Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer …

E Élez, I Kocáková, T Höhler, UM Martens… - Annals of …, 2015 - Elsevier
Background Integrins are involved in tumour progression and metastasis, and differentially
expressed on colorectal cancer (CRC) cells. Abituzumab (EMD 525797), a humanised …

Tumor necrosis factor alpha promoter polymorphism at position‐238 is associated with chronic active hepatitis C infection

T Höhler, A Kruger, G Gerken… - Journal of medical …, 1998 - Wiley Online Library
Tumor necrosis factor α (TNF‐α) is involved in the pathogenesis of chronic hepatitis C virus
infection. The gene for TNF‐α is encoded in the major histocompatibility locus (MHC). Two …

[HTML][HTML] Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM …

…, RL Lopez, JK Roh, V Chistyakov, T Höhler… - Annals of …, 2016 - Elsevier
Background The combination of aflibercept with FOLFIRI has been shown to significantly
prolong overall survival in patients with metastatic colorectal cancer (mCRC) after progression …